Elucid Names Dr. Amir Ahmadi as a Chief Scientific Advisor

March 27, 2025—Elucid recently announced that cardiologist Amir Ahmadi, MD, has joined as a Chief Scientific Advisor and will lead the company’s clinical strategy. The company advised that this and other appointments have been made as Elucid prepares for the commercial launch of its PlaqueIQ image analysis software.

According to Elucid, Dr. Ahmadi is Clinical Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai in New York, New York, as well as Director of Inpatient Cardiology and Codirector of the Cardiac Intensive Care Unit at Mount Sinai Morningside.

Dr. Ahmadi’s clinical practice focuses on cardiac intensive care, multimodality imaging, and prevention cardiology of early atherosclerosis detection and personalized treatment. His ongoing clinical practice and research involve using CT coronary angiography to detect and treat subclinical atherosclerosis, understand myocardial infarction mechanisms, and investigate the relationship between high-risk plaque features and ischemia, stated Elucid in the press release.

Additionally, the company has appointed Carol Holt as Vice President of Clinical Development, Kevin Mathews as Senior Vice President of Marketing, and Amy Pyke as Senior Vice President of Market Access.

Last year, Elucid announced that Kelly Huang, PhD, was named President and Chief Executive Officer.

On October 1, 2024, the company announced FDA clearance of PlaqueIQ, which is intended to provide physicians with comprehensive patient, vessel, and lesion plaque composition and quantification. The software offers potential insights on heart attack and stroke risk prediction and personalized treatment decisions, noted Elucid.